Best drug reference app for physicians, nurses and pharmacists

Two of the nine apps here cost nothing, and both are better than a paid-first roundup will usually admit. Medscape is free with no in-app purchases at all, and carries a larger drug list than the free Epocrates tier along with a multi-drug interaction checker, a pill identifier, several hundred calculators and free CME. It is funded by advertising, which is the honest trade you are making. OpenEvidence is free to NPI-verified US clinicians and answers questions out of the published literature with citations, though it is an answer engine rather than a drug compendium.

The wall you hit on a free tier is usually a specific one rather than a general sense of limitation. On Epocrates it is the interaction checker stopping at 30 medications, which sounds generous until you are reconciling a nursing home list. On Medscape it is depth: it will tell you a drug needs renal adjustment more readily than it will walk you through exactly what to adjust it to. On OpenEvidence it is the shape of the tool, because it answers the question you thought to ask.

That last point is worth sitting with, because it is the one that survives every price comparison. A reference is a waiting tool. The interaction that harms a patient is very rarely the one the prescriber suspected and looked up. It is the one nobody had a reason to check, which is why adding a second reference to your phone tends not to move the number of caught problems much, and why clinical decision support software is treated as a separate category from reference in the first place.

The spread across this table runs from zero to a number the vendor will not print. That looks irrational until you notice what predicts it, which is not quality. It is who signs the invoice. Everything sold to a clinician holding a credit card carries a published price: epocrates+ at $179.99 a year, Lexidrug at $29.99 a month, Sanford Guide and Davis's at $39.99 a year. Everything sold to a procurement department carries none.

Wolters Kluwer demonstrates both halves of this at once. It publishes $29.99 a month for Lexidrug on the App Store, and publishes nothing whatsoever for UpToDate, whose store will not quote you until you have declared a country and a professional role, and which routes any organization with 20 or more users to enterprise sales. Same vendor, same underlying drug data, opposite disclosure policy. Micromedex behaves the same way: no list price, institutional quote only.

The practical consequence is that you cannot benchmark an institutional purchase against anything public. Software directories fill that vacuum with confident figures that no vendor ever published, and those figures disagree with each other by hundreds of dollars for the same product. We do not repeat them anywhere on this site. If you are buying for a group rather than yourself, the mechanics of getting a comparable number are covered in our guide to institutional and group license pricing.

This is the dullest advice here and the most likely to save you a few hundred dollars a year. Open your EHR and look for a drug reference link inside the medication activity, because Lexidrug is licensed into Epic, MEDITECH and Cerner across a large number of US hospitals. Open your health system's or medical school's clinical resources page, since academic health sciences libraries routinely license UpToDate, DynaMed, Lexidrug or Micromedex with off-site access through an institutional login. Check your professional society, because DynaMed comes with ACP membership.

Trainees and nurse practitioners are the two groups most likely to be paying for something they already have, usually because the access exists but nobody told them. Ask a medical librarian. It takes one email and it frequently ends the search. Then buy against whatever gap is genuinely left rather than against a general feeling that you should own a drug app.

Run the comparison honestly and a pattern shows up that no amount of extra reference depth fixes. Every tool here answers a question you brought to it. The prescribing decision in front of you is usually blocked by more than one thing at once: an interaction, plus a renal dose that needs adjusting, plus an allergy nobody flagged, plus a drug-disease contraindication sitting quietly in the problem list. Checking those in a reference means four separate lookups, and on a busy afternoon the fourth one does not happen.

Prescriber.io is built for that specific moment rather than for reading. You enter the drug or the scenario once, and the interaction check, the contraindication and allergy flags, the renal and hepatic dose adjustments and guideline-based alternatives come back together in one card, with sources cited on each flag. It is decision support, which means the software checks and suggests and a licensed clinician verifies against official sources and signs. It does not diagnose and it does not prescribe.

It is also not a replacement for a clinical library, and this page would be worth less if it pretended otherwise. If your job involves reading up on a condition end to end, you still need a reference, and one of the free ones may well be enough. If your bottleneck is the check that has to happen reliably before your signature, that is a different purchase. We publish every per-clinician rate we charge, including the multi-seat one, on our pricing page.